Free Trial
NASDAQ:ACTU

Actuate Therapeutics (ACTU) Stock Price, News & Analysis

Actuate Therapeutics logo
$8.72 +0.11 (+1.28%)
Closing price 09/4/2025 04:00 PM Eastern
Extended Trading
$8.65 -0.07 (-0.80%)
As of 09/4/2025 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Actuate Therapeutics Stock (NASDAQ:ACTU)

Key Stats

Today's Range
$8.55
$9.22
50-Day Range
$5.66
$8.72
52-Week Range
$5.47
$11.99
Volume
86,042 shs
Average Volume
51,757 shs
Market Capitalization
$180.94 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$20.33
Consensus Rating
Buy

Company Overview

Actuate Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
53rd Percentile Overall Score

ACTU MarketRank™: 

Actuate Therapeutics scored higher than 53% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Actuate Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Actuate Therapeutics has only been the subject of 2 research reports in the past 90 days.

  • Read more about Actuate Therapeutics' stock forecast and price target.
  • Price to Book Value per Share Ratio

    Actuate Therapeutics has a P/B Ratio of 872.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Short Interest

    There is no current short interest data available for ACTU.
  • Dividend Yield

    Actuate Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Actuate Therapeutics does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for ACTU.
  • News Sentiment

    Actuate Therapeutics has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Actuate Therapeutics this week, compared to 2 articles on an average week.
  • Search Interest

    3 people have searched for ACTU on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.
  • MarketBeat Follows

    2 people have added Actuate Therapeutics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Actuate Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,499,988.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    69.34% of the stock of Actuate Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Read more about Actuate Therapeutics' insider trading history.
Receive ACTU Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Actuate Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ACTU Stock News Headlines

Q3 Earnings Forecast for ACTU Issued By B. Riley
What's the Best Way to Lower RMD Taxes?
Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain retirement accounts. Without the right strategy, these withdrawals can significantly increase your tax bill and shrink your nest egg. SmartAsset outlines six strategies that could help reduce your RMDs and potentially lower your tax burden. Their free tool can match you with vetted fiduciary financial advisors in your area—professionals legally bound to act in your best interest.tc pixel
See More Headlines

ACTU Stock Analysis - Frequently Asked Questions

Actuate Therapeutics' stock was trading at $7.96 at the beginning of 2025. Since then, ACTU shares have increased by 9.5% and is now trading at $8.72.

Actuate Therapeutics, Inc. (NASDAQ:ACTU) posted its earnings results on Thursday, August, 14th. The company reported ($0.30) earnings per share for the quarter, missing analysts' consensus estimates of ($0.19) by $0.11.

Actuate Therapeutics (ACTU) raised $27 million in an IPO on Tuesday, August 13th 2024. The company issued 3,000,000 shares at a price of $8.00-$10.00 per share. Titan Partners acted as the underwriter for the IPO and Newbridge Securities Corp. was co-manager.

Actuate Therapeutics' top institutional investors include BIOS Capital Management LP (48.68%), Voss Capital LP (1.40%), Geode Capital Management LLC (0.58%) and Gleason Group Inc. (0.10%). Insiders that own company stock include Todd S Thomson, Leslie W Kreis, Equity Cof Lp Bios and Aaron GL Fletcher.
View institutional ownership trends
.

Shares of ACTU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Actuate Therapeutics investors own include Arch Capital Group (ACGL), Adobe (ADBE), Analog Devices (ADI), Alnylam Pharmaceuticals (ALNY), Aileron Therapeutics (ALRN), Amgen (AMGN) and AstraZeneca (AZN).

Company Calendar

Last Earnings
8/14/2025
Today
9/04/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ACTU
Previous Symbol
NASDAQ:ACTU
CIK
1652935
Web
N/A
Fax
N/A
Employees
10
Year Founded
N/A

Price Target and Rating

High Price Target
$21.00
Low Price Target
$20.00
Potential Upside/Downside
+133.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$27.28 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
-281.83%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.73
Quick Ratio
0.73

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.01 per share
Price / Book
872.00

Miscellaneous

Outstanding Shares
20,750,000
Free Float
6,360,000
Market Cap
$180.94 million
Optionable
N/A
Beta
N/A

Social Links

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NASDAQ:ACTU) was last updated on 9/5/2025 by MarketBeat.com Staff
From Our Partners